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Growing evidence suggests that immune dysregulation may be involved in depressive disorders, but the exact nature of this
association is still unknown and may be restricted to speciﬁc subgroups. This study examines the association between
depressive disorders, depression characteristics and antidepressant medication with inﬂammation in a large cohort of controls
and depressed persons, taking possible sex differences and important confounding factors into account. Persons (18–65 years)
with a current (N¼1132) or remitted (N¼789) depressive disorder according to DSM-IV criteria and healthy controls (N¼494)
were selected from the Netherlands Study of Depression and Anxiety. Assessments included clinical characteristics (severity,
duration and age of onset), use of antidepressant medication and inﬂammatory markers (C-reactive protein (CRP), interleukin-6
(IL-6), tumor necrosis factor-alpha (TNF-a)). After adjustment for sociodemographics, currently depressed men, but not women,
had higher levels of CRP (1.33 versus 0.92mgl
 1, Po0.001, Cohen’s d¼0.32) and IL-6 (0.88 versus 0.72pgml
 1, P¼0.01,
Cohen’s d¼0.23) than non-depressed peers. Associations reduced after considering lifestyle and disease indicators —
especially body mass index — but remained signiﬁcant for CRP. After full adjustment, highest inﬂammation levels were found in
depressed men with an older age of depression onset (CRP, TNF-a). Furthermore, inﬂammation was increased in men using
serotonin–norepinephrine reuptake inhibitors (CRP, IL-6) and in men and women using tri- or tetracyclic antidepressants (CRP),
but decreased among men using selective serotonin reuptake inhibitors (IL-6). In conclusion, elevated inﬂammation was
conﬁrmed in depressed men, especially those with a late-onset depression. Speciﬁc antidepressants may differ in their effects
on inﬂammation.
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Introduction
Depression is a complex heterogeneous disorder, which may
needasimilarlyheterogeneousofferoftreatmentpossibilities.
Currently available antidepressant medications largely
target monoamine pathways, but treatment of depression is
only effective in about a third to a half of patients.
1,2
Identiﬁcation of additional pathophysiological pathways
involved in depression (subtypes) is needed to guide the
development of alternative treatment strategies. Increasing
interest has been directed to immune dysregulation in
depression. Recently, two meta-analyses have shown that
inﬂammatory marker levels such as C-reactive protein (CRP),
interleukin (IL)-6 and tumor necrosis factor alpha (TNF-a)
are increased in depressed persons compared with non-
depressed subjects.
3,4
Although the results of these meta-analyses are promising,
the evidence for immune dysregulation in depression is not
conclusive. A substantial portion of studies included in these
meta-analyses did not adequately adjust for possible con-
founding factors. The association between depression and
inﬂammationappearedmuchsmaller,althoughstillpresent,in
studies adjusting for body mass index (BMI).
4 The effect
estimate after a more complete adjustment (including several
lifestyle anddiseasefactors)isnotentirelyclear. Also,mostof
the larger studies examining depression and inﬂammation
have used depressive symptoms questionnaires instead of
assessing psychiatric diagnoses by means of clinical inter-
views. The former is much more prone to confounding by
somatic health as a person can score high on these
questionnaires based on having many physical complaints.
Furthermore, a large part of previous studies has been
conducted within older populations. More studies within
younger age samples are therefore needed.
Next to these general limitations, meta-analyses have
foundverylargeheterogeneityacrossstudies.
3,4Itisplausible
that immune dysregulation is not generally present
in depression, but restricted to particular subgroups of
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www.nature.com/tpdepressed persons. Several factors that could inﬂuence the
depression–inﬂammation relationship need further investiga-
tion to help delineate the depressed person with immune
dysregulation. This is important to give direction to whom new
treatment strategies could be targeted.
First, sex differences might exist, but results are thus far
inconsistent. Stronger, weaker or similar effects have been
found for women compared with men for different inﬂamma-
tory markers.
4,5 Inﬂammation levels ﬂuctuate throughout
female life according to hormonal changes owing to phase
of menstrual cycle, use of hormonal contraceptives, meno-
pause and use of estrogens,
6–8 which might inﬂuence the
relationship between depression and inﬂammation.
Second, it is largely unknown whether speciﬁc depression
characteristics indicate immune dysregulation.
3 In line with a
dose-responseassumption,moresevereand/ormorechronic
disorders can be hypothesized to show the most inﬂamma-
tion.
9,10 In addition, late-onset depression has been asso-
ciated with family history of vascular disease
7 and
atherosclerosis.
11,12 As immune dysregulation is critically
involved in vascular disease,
13 it can be hypothesized that
increased inﬂammation is speciﬁcally present in those with
late-onset depressive disorders.
Third, antidepressant medication might inﬂuence inﬂam-
mation levels and this effect might differ across type of
medication. As summarized by Miller et al.,
14 several studies
showed that antidepressant treatment, mainly selective
serotonin reuptake inhibitors, was associated with decreases
in inﬂammatory markers. In contrast, recent results of two
large studies suggest that use of antidepressants, mainly
tricyclic antidepressants (TCA), is associated with elevated
inﬂammation levels.
15
To address the issues raised above, the ﬁrst aim of the
present study was to examine the association between
diagnosed depressive disorders and inﬂammatory markers
(CRP, IL-6 and TNF-a), using a large and relatively young
cohort ofdepressedpersons andcontrols, taking possible sex
differences and important confounding factors into account.
The second aim was to investigate whether speciﬁc depres-
sioncharacteristics(severity,durationandageofonset)could
further delineate the depressed person with increased
inﬂammation. Lastly, possible effects of (speciﬁc types of)
antidepressant medication on inﬂammation levels were
examined.
Subjects and methods
Sample. The Netherlands Study of Depression and Anxiety
(NESDA) is an ongoing cohort study designed to investigate
the long-term course and consequences of depressive and
anxiety disorders. Participants were 18 to 65 years old at
baseline assessment in 2004–2007 and were recruited from
the community (19%), general practice (54%) and secondary
mental health care (27%). A total of 2981 persons were
included, consisting of persons with a current or past
depressive and/or anxiety disorder and healthy controls. A
detailed description of the NESDA study design and
sampling procedures can be found elsewhere.
16 The
research protocol was approved by the Ethical Committee
of participating universities, and after complete description of
the study all respondents provided written informed consent.
During the baseline interview, presence of depressive
disorder (major depressive disorder, dysthymia) and anxiety
disorder (social phobia, generalized anxiety disorder,
panic disorder and agoraphobia) was established using the
Composite Interview Diagnostic Instrument (CIDI) according
to DSM-IV criteria.
17 The CIDI is a highly reliable and valid
instrument for assessing depressive and anxiety disorders
18
and was administered by specially trained research staff. In
addition, the severity of depression was measured in
all participants using the 28-item self-report Inventory of
Depressive Symptoms (IDS).
19 For the present analyses we
selected persons with a current (that is, past 6 months;
N¼1158) or remitted (lifetime, but not current; N¼815)
depressive disorder and healthy controls without any lifetime
depressive or anxiety disorder and an IDS score below 14
(N¼506). Of these 2479 persons, 64 were excluded because
of missing information on inﬂammatory markers, leaving a
sample of 2415 persons for the present study. Persons with
missing data on inﬂammation did not differ from included
persons in terms of sex, age, years of education and
depressive disorder status.
Inﬂammatory markers. Markers of inﬂammation were
assessed at the baseline NESDA measurement and
included CRP, IL-6 and TNF-a. Fasting blood samples of
NESDA participants were obtained in the morning around
0800 hours and kept frozen at  701C. CRP and IL-6 were
assayed at the Clinical Chemistry department of the VU
University Medical Center. High-sensitivity plasma levels of
CRP were measured in duplicate by an in-house ELISA
based on puriﬁed protein and polyclonal anti-CRP antibodies
(Dako, Glostrup, Denmark). Intra- and inter-assay
coefﬁcients of variation were 5% and 10%, respectively.
Plasma IL-6 levels were measured in duplicate by a high
sensitivity ELISA (PeliKine Compact ELISA, Sanquin,
Amsterdam, The Netherlands). Intra- and inter-assay
coefﬁcients of variation were 8% and 12%, respectively.
Plasma TNF-a levels were assayed in duplicate at Good
Biomarker Science (Leiden, The Netherlands), using a high-
sensitivity solid phase ELISA (Quantikine HS Human TNF-a
Immunoassay, R&D systems, Minneapolis, MN, USA). Intra-
and inter-assay coefﬁcients of variation were 10% and 15%,
respectively.
Depression characteristics. Next to CIDI depressive
disorder diagnosis, depression characteristics included
depressive symptoms severity as measured by the IDS,
and depressive symptoms duration, using the Life Chart
method,
20 in which a detailed account of the presence of
depressive symptoms during the past 4 years was assessed.
From this, the percent of time patients reported depressive
symptoms was computed. Additionally, age of depression
onset was derived from the CIDI interview.
Antidepressant medication. Medication use was assessed
based on drug container inspection of all drugs used in
the past month and classiﬁed according to the World
Health Organization Anatomical Therapeutic Chemical
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21 Antidepressant medication was only con-
sidered when taken on a regular basis (at least 50% of
the time) and included selective serotonin reuptake inhi-
bitors (SSRI; N06AB), serotonin–norepinephrine reuptake
inhibitors (SNRI; N06AX16 and N06AX21), TCA (N06AA)
and tetracyclic antidepressants (TeCA; N06AX03, N06AX05
and N06AX11).
Covariates. Sociodemographic characteristics included
age, sex and years of education. As lifestyle characteristics
can be associated with both depression and inﬂammation,
smoking status (never, former and current; assessed by self-
report), alcohol intake (o1, 1–14 (women) / 1–21 (men), 414
(women)/421 (men) drinks per week; based on general
guidelines that are used in health organizations in the
Netherlands
22 and as used in other studies
23), BMI (weight
in kilograms divided by height in meters squared) and
physical activity (measured with the International Physical
Activity Questionnaire
24 in MET-minutes (ratio of energy
expenditure during activity compared with rest times the
number of minutes performing the activity) per week)
were assessed. In addition, several disease related
covariates were taken into account including presence of
cardiovascular disease (assessed by self-report supported
by appropriate medication use (see ref. 25 for detailed
description), presence of diabetes (fasting plasma glucose
level X7.0mmoll
 1 or use of anti-diabetic medication (A10)),
and the number of other self-reported chronic diseases for
which persons received treatment (including lung disease,
osteoarthritis or rheumatic disease, cancer, ulcer, intestinal
problem, liver disease, epilepsy and thyroid gland disease).
As suggested by Howren et al.,
4 to control for possible
medication effects, we assessed statin use (C10AA, C10B)
and use of systemic anti-inﬂammatory medication (M01A,
M01B, A07EB and A07EC). In women, we additionally
assessed use of sex hormones (self-reported use of oral
contraceptives or ATC code G03), self-reported menstrual
cycle phase (menstrual (0–3 days since start last
menstruation), follicular (4–13 days), luteal (14–32 days))
and self-reported postmenopausal status (yes/no).
Statistical analyses. All analyses were conducted using
SPSS version 15.0 statistical software (SPSS Inc., Chicago,
IL, USA). Differences in baseline characteristics across sex
were tested for statistical signiﬁcance using w
2-statistics for
dichotomous and categorical variables and independent t-
tests and Mann–Whitney U-tests for normally and non-
normally distributed continuous variables. For subsequent
analyses, CRP, IL-6 and TNF-a were ln-transformed to
normalize distributions and presented back-transformed.
Associations between baseline characteristics and inﬂam-
matory markers were tested using independent samples t-
tests for dichotomous variables, one-way analyses of
variance for categorical variables and Pearson’s corre-
lations for continuous variables.
Associations between depressive disorders and inﬂamma-
tory markers were examined using analyses of (co)variance
and (adjusted) means across depression groups (no, remitted
and current) were presented. To take the effects of important
confounding factors into account, three different models were
tested: unadjusted, adjustedforsociodemographics (sex,age
and education) and additionally adjusted for lifestyle and
disease (smoking status, alcohol intake, BMI, physical
activity, cardiovascular disease, diabetes, number of other
chronic diseases, statins and anti-inﬂammatory medication).
To investigate possible sex differences, we tested for sex
interactions byincludingasex-depressivedisorderinteraction
term. When present, analyses were repeated sex stratiﬁed.
Forsigniﬁcantassociations,Cohen’sdwascalculatedinorder
to assess effect size.
To test whether speciﬁc depression characteristics were
related to elevated inﬂammation levels, we performed linear
regression analyses for each depression characteristic within
the sample of persons with a current depressive disorder. Sex
interactions were again tested and if present, shown sex
stratiﬁed.
To investigate possible effects of antidepressant medica-
tions, adjusted means of inﬂammation levels across different
medication groups were calculated using analyses of covar-
iance and presented sex stratiﬁed in case sex interaction was
present.
Results
Baseline characteristics of the total sample and for men
(N¼800) and women (N¼1615) separately are shown in
Table 1. Women were younger, less often smokers, more
often non-drinkers,hada lower BMI, lessoftencardiovascular
disease or diabetes and less often used statins than men. In
addition, women had higher levels of CRP, but lower levels of
IL-6 and TNF-a than men. In men, older age, less education,
smoking, heavy or non-drinking, higher BMI, lower physical
activity, cardiovascular disease, diabetes, higher number of
other chronic diseases, statin use and use of anti-inﬂamma-
tory medication were associated with higher levels of at least
one of the inﬂammatory markers (data not shown). In women,
similar associations were found, except for smoking, heavy
drinking, and physical activity. The Pearson’s correlations
between inﬂammatory markers were modest, likely reﬂecting
only partial biological overlap, and somewhat higher in men
(CRP-IL-6: r¼0.40; CRP-TNF-a: r¼0.22; IL-6–TNF-a:
r¼0.17) than in women (CRP-IL-6: r¼0.28; CRP-TNF-a:
r¼0.10; IL-6–TNF-a: r¼0.09).
Table 2 shows (adjusted) mean inﬂammation levels across
depression groups (controls, remitted and current depressive
disorder) based on analyses of (co) variance. In the total
sample, current depressive disorders were signiﬁcantly
associated with higher levels of CRP and IL-6 in the
unadjusted model. After additional adjustment for socio-
demographics, lifestyle and disease factors, these associa-
tions disappeared. No associations were found for TNF-a. For
current depressive disorders, sex interactions were found for
CRP (P-interactiono0.001) and IL-6 (P-interaction¼0.009),
but not TNF-a (P-interaction¼0.99).
In men, after adjustment for sociodemographics, a current
depressive disorder was associated with higher CRP levels
(1.33 versus 0.92mgl
 1, Po0.001, Cohen’s d¼0.32) and
IL-6 levels (0.88 versus 0.72pgml
 1, P¼0.01, Cohen’s
d¼0.23). Even after full adjustment for lifestyle and disease
factors, men with a current depressive disorder had higher
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Translational PsychiatryCRP levels compared with controls (1.29 versus 1.04mgl
 1,
P¼0.02, Cohen’s d¼0.21), and marginally higher IL-6 levels
(0.87 versus 0.76pgml
 1, P¼0.10, Cohen’s d¼0.15). No
associations with TNF-a were found in men. Overall, BMI
weakened the associations most, followed by number of other
chronic diseases. Smoking status, alcohol use and physical
activity weakened associations slightly further. Adjustment for
cardiovascular disease, diabetes, statins and anti-inﬂamma-
tory medication hardly affected associations.
In women, depressive disorders were not associated with
inﬂammatory markers before or after adjustment. Although
sex hormone use, menstrual cycle phase and postmenopausal
status were strongly associated with inﬂammation levels,
additional adjustment for these factors did not change the
results for women. Also, there were no signiﬁcant postmeno-
pausal status-depression interactions in the associations with
inﬂammation levels (all P40.40) suggesting that associations
between depression and inﬂammation appeared absent in
both premenopausal (N¼1076) and postmenopausal women
(N¼539).
To investigate whether speciﬁc depression characteristics
(severity, duration and age of onset) were associated with
higher inﬂammation levels, linear regression analyses were
performed within the subgroup of currently depressed
persons (N¼1132; Table 3). Women with more severe
depressive symptoms had higher levels of TNF-a.N o
associationswerefoundfordurationofdepressivesymptoms.
Menwithanolderageofdepressiononsethadhigherlevelsof
CRP and TNF-a than those with a younger age of depression
onset.
Lastly, the association between antidepressant medication
use and inﬂammation levels was examined. To incorporate
possible differences in depression severity between persons
who were or were not using antidepressants, we selected a
Table 1 Baseline characteristics
Total sample
(N¼2415)
Men
(N¼800)
Women
(N¼1615)
P
a
Sociodemographics
Age (years), mean (s.d.) 41.8 (12.9) 43.7 (12.6) 40.9 (12.9) o0.001
Education (years), mean (s.d.) 12.2 (3.3) 12.0 (3.3) 12.2 (3.3) 0.12
Lifestyle and Disease
Smoking status 0.003
Never, % 27.9 23.5 30.1
Former, % 32.7 34.3 31.9
Current, % 39.4 42.3 38.0
Alcohol intake o0.001
o1 Drink a week, % 32.9 22.9 37.8
1–14 (women) / 1–21 (men) drinks a week, % 55.9 66.5 50.7
414 (women) / 421 (men) drinks a week, % 11.2 10.6 11.5
Body mass index, mean (s.d.) 25.7 (5.1) 26.3 (4.6) 25.4 (5.3) o0.001
Physical activity (MET-min per week), mean (s.d.) 3673 (3026) 3758 (3324) 3630 (2867) 0.36
Cardiovascular disease, % 5.6 9.4 3.8 o0.001
Diabetes, % 4.9 7.8 3.5 o0.001
Number of other chronic diseases, mean (s.d.) 0.4 (0.7) 0.4 (0.7) 0.4 (0.7) 0.11
Statin use, % 6.6 10.9 4.5 o0.001
Anti-inﬂammatory medication use, % 4.2 4.0 4.3 0.75
Depression characteristics
Depressive disorder 0.004
Controls, % 20.5 24.1 18.6
Remitted depressive disorder, % 32.7 29.8 34.1
Current depressive disorder, % 46.9 46.1 47.2
Within currently depressed cases (N¼1132)
Severity (IDS score), mean (s.d.) 32.5 (12.2) 32.9 (12.6) 32.3 (12.1) 0.46
Duration (% of time depressed), mean (s.d.) 38.5 (30.3) 40.9 (31.6) 37.4 (29.6) 0.07
Age of depression onset (years), mean (s.d.) 27.1 (12.5) 29.7 (13.3) 25.9 (11.8) o0.001
Antidepressant use 0.13
No antidepressant, % 57.2 57.5 57.1
SSRI, % 28.8 25.7 30.3
SNRI, % 7.2 9.5 6.2
TCA, % 3.8 3.5 3.9
TeCA, % 2.9 3.8 2.5
Inﬂammatory markers
C-reactive protein (mgl
 1), median (IQR) 1.22 (0.54–3.02) 1.09 (0.51–2.67) 1.30 (0.56–3.21) 0.001
Interleukin-6 (pgml
 1), median (IQR) 0.76 (0.50–1.25) 0.81 (0.53–1.36) 0.72 (0.49–1.19) 0.003
Tumor necrosis factor-alpha (pgml
 1), median (IQR) 0.80 (0.60–1.10) 0.80 (0.60–1.10) 0.70 (0.60–1.10) 0.001
Abbreviations: IDS, inventory of depressive symptoms; IQR, interquartile range; s.d., standard deviation; SSRI, selective serotonin reuptake inhibitor; SNRI,
serotonin–norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressant.
aBased on w
2-test for dichotomous and categorical variables, and independent samples t-test for continuous variables testing the difference between men and
women; for inﬂammatory markers the Mann–Whitney U-test was used.
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Translational PsychiatryTable 2 Adjusted mean inﬂammation levels across depression groups
Controls Remitted depressive disorder Current depressive disorder
Mean (s.e.) P Mean (s.e.) P Mean (s.e.) P
CRP, mgl
 1,a
Total sample N¼494 N¼789 N¼1132
Unadjusted 1.09 (1.06) Ref 1.25 (1.04) 0.05 1.40 (1.04) o0.001
Adjusted
b 1.17 (1.06) Ref 1.24 (1.04) 0.38 1.36 (1.04) 0.02
Adjusted
c 1.27 (1.05) Ref 1.26 (1.04) 0.91 1.30 (1.03) 0.66
Men N¼193 N¼238 N¼369
Unadjusted 0.83 (1.09) Ref 1.14 (1.08) 0.005 1.36 (1.06) o0.001
Adjusted
b 0.92 (1.08) Ref 1.09 (1.08) 0.13 1.33 (1.06) o0.001
Adjusted
c 1.04 (1.08) Ref 1.03 (1.07) 0.96 1.29 (1.06) 0.02
Women N¼301 N¼551 N¼763
Unadjusted 1.29 (1.07) Ref 1.30 (1.05) 0.94 1.42 (1.05) 0.29
Adjusted
b 1.36 (1.07) Ref 1.34 (1.05) 0.82 1.36 (1.05) 0.96
Adjusted
c 1.45 (1.07) Ref 1.38 (1.05) 0.57 1.30 (1.04) 0.16
IL-6, pgml
 1,a
Total sample N¼494 N¼789 N¼1132
Unadjusted 0.72 (1.04) Ref 0.75 (1.03) 0.49 0.80 (1.03) 0.04
Adjusted
b 0.74 (1.04) Ref 0.74 (1.03) 0.88 0.79 (1.03) 0.24
Adjusted
c 0.78 (1.04) Ref 0.74 (1.03) 0.42 0.77 (1.03) 0.91
Men N¼193 N¼238 N¼369
Unadjusted 0.68 (1.07) Ref 0.82 (1.06) 0.03 0.89 (1.05) 0.001
Adjusted
b 0.72 (1.07) Ref 0.80 (1.06) 0.20 0.88 (1.05) 0.01
Adjusted
c 0.76 (1.07) Ref 0.78 (1.06) 0.72 0.87 (1.05) 0.10
Women N¼301 N¼551 N¼763
Unadjusted 0.74 (1.06) Ref 0.71 (1.04) 0.55 0.75 (1.04) 0.86
Adjusted
b 0.77 (1.06) Ref 0.71 (1.04) 0.22 0.75 (1.03) 0.63
Adjusted
c 0.80 (1.06) Ref 0.72 (1.04) 0.13 0.73 (1.03) 0.14
TNF-a,p gm l
 1,a
Total sample N¼494 N¼789 N¼1132
Unadjusted 0.82 (1.03) Ref 0.82 (1.02) 0.99 0.86 (1.02) 0.23
Adjusted
b 0.84 (1.03) Ref 0.82 (1.02) 0.60 0.85 (1.02) 0.59
Adjusted
c 0.85 (1.03) Ref 0.82 (1.02) 0.43 0.84 (1.02) 0.78
Men N¼193 N¼238 N¼369
Unadjusted 0.84 (1.04) Ref 0.84 (1.04) 0.90 0.87 (1.03) 0.41
Adjusted
b 0.85 (1.04) Ref 0.83 (1.04) 0.65 0.87 (1.03) 0.70
Adjusted
c 0.88 (1.04) Ref 0.83 (1.04) 0.33 0.86 (1.03) 0.69
Women N¼301 N¼551 N¼763
Unadjusted 0.81 (1.04) Ref 0.81 (1.03) 0.97 0.85 (1.02) 0.34
Adjusted
b 0.83 (1.04) Ref 0.81 (1.03) 0.76 0.84 (1.02) 0.74
Adjusted
c 0.84 (1.04) Ref 0.82 (1.03) 0.70 0.83 (1.02) 0.90
Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6; TNF-a, tumor necrosis factor-alpha.
aTo normalize distributions CRP, IL-6 and TNF-a were ln-transformed; for interpretation purposes presented means were back transformed.
bBased on analyses of (co)variance; adjusted for sex, age and education.
cAdditionally adjusted for smoking status, alcohol intake, body mass index, physical activity, cardiovascular disease, diabetes, number of other chronic diseases,
statins and anti-inﬂammatory medication.
Table 3 Association
a of depression characteristics with inﬂammatory markers in persons with current depressive disorders (N¼1132)
CRP
b IL-6
b TNF-a
b
Depression characteristic b P b P b P
Severity (IDS score)  0.020 0.47 0.038 0.22 0.040 0.20
Men  0.048 0.36
Women 0.085 0.02
Duration of depressive symptoms  0.005 0.87  0.017 0.58 0.012 0.70
Age of depression onset 0.064 0.04  0.002 0.95 0.043 0.22
Men 0.140 0.003 0.149 0.004
Women 0.016 0.67  0.025 0.55
Abbreviations: CRP, C-reactive protein; IDS, inventory of depressive symptoms; IL-6, interleukin-6; TNF-a, tumor necrosis factor-alpha.
aBased on linear regression analyses adjusted for (sex), age, education, smoking status, alcohol intake, body mass index, physical activity, cardiovascular disease,
diabetes, number of other chronic diseases, statins, anti-inﬂammatory medication; sex-speciﬁc associations are shown in case P sex interaction p0.05.
bCRP, IL-6 and TNF-a were ln-transformed to normalize distributions.
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Translational Psychiatrycontrol group of medication-free depressed persons with a
current diagnosis and an IDS score X25 (N¼426). In this
medication-free reference group the mean IDS score was
comparable to the other medication groups. As effects of TCA
and TeCA users were comparable, they were grouped
together to increase numbers. Sex interactions in the
association between antidepressant medication group (no
medication, SSRI, SNRI and TCA/TeCA) and inﬂammatory
markers were found (CRP: P-interaction¼0.06, IL-6:
P-interaction¼0.02; TNF-a: P-interaction¼0.90). Therefore,
Figure 1shows adjustedmeaninﬂammationlevels comparing
antidepressant users with medication-free persons, for men
and women separately. Increased levels of CRP were found
for men using SNRI (1.98 versus 1.21mgl
 1, P¼0.02,
Cohen’s d¼0.44) or TCA/TeCA (2.05 versus 1.21mgl
 1,
P¼0.02, Cohen’s d¼0.48) as compared with medication-
free depressed men. A trend for higher CRP in TCA/TeCA
users was also found for women (2.10 versus 1.53mgl
 1,
P¼0.08, Cohen’s d¼0.28). In men only, IL-6 levels were
lower in SSRI users (0.70 versus 0.91pgml
 1, P¼0.02,
Cohen’s d¼ 0.32) and considerably increased in SNRI
users (1.37 versus 0.91pgml
 1, P¼0.01, Cohen’s d¼0.49)
compared with medication-free depressed men. No associa-
tions were found for TNF-a. For comparison, inﬂammation
levels in persons with cardiovascular disease were
1.84mgl
 1 for CRP and 1.06pgml
 1 for IL-6, suggesting
that the putative effects of antidepressant medication are at
least of similar magnitude as having cardiovascular disease.
Asantidepressantmedicationeffectswerefound,wechecked
whethertheseinﬂuencedtheﬁndingsfromTables2and3,but
results remained similar after additional adjustment for
antidepressant medication group.
Discussion
The present study examined the association between
depressive disorders, depression characteristics and anti-
depressant medication with inﬂammation in a large cohort of
depressed persons and controls. After taking a large set of
possibly confounding factors into account, it was found that
men with current depressive disorders had higher levels of
CRP, and marginally higher levels of IL-6, but not of TNF-a.
No overall associations were found in women. Increased
inﬂammationwasinparticularfoundindepressedmenwithan
older age of depression onset (CRP, TNF-a). Users of SNRI
(men only), TCA and TeCA had increased levels of CRP
and IL-6, whereas men using SSRI had signiﬁcantly lower
levels of IL-6.
Our results conﬁrm previous ﬁndings of immune dysregula-
tion in depressed persons.
3,4 In men, effect sizes for current
depression were small to moderate for both CRP and IL-6.
These effect sizes are comparable to those reported by the
meta-analysis of Howren,
4 in which stronger effects were
found for studies using clinical interviews compared with
studies using self-report questionnaires. Compared with
symptom questionnaires, a depressive disorder diagnosis is
less confounded by somatic health problems. Together with
the fact that our results were elaborately adjusted for possibly
confounding factors, our ﬁndings suggest a true relationship
between depression and inﬂammation in men.

Figure 1 Adjustedmeaninﬂammatorylevelsacrossmedicationgroupsandsex
based on analyses of covariance (ANCOVA) adjusted for age, education, smoking
status, alcohol intake, body mass index (BMI), physical activity, cardiovascular
disease, diabetes, number of other chronic diseases, statins and anti-inﬂammatory
medication; to normalize distributions C-reactive protein (CRP), Interleukin-6 (IL-6)
and Tumor necrosis factor-alpha (TNF-a) were ln-transformed, for interpretation
purposespresentedmeanswerebacktransformed.Abbreviations:IDS,inventoryof
depressive symptoms score; SNRI, serotonin–norepinephrine reuptake inhibitor;
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TeCA,
tetracyclic antidepressant.
1Current depressive disorder and IDS X25 without
medication use (¼reference); only signiﬁcant differences from reference are
shown: *Po0.10; **Po0.05.
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tion were found in women. This is in line with results from
another large and relatively young cohort study in which
history of depression was associated with CRP levels in men,
but not women.
5 Hormonal changes throughout female
life due to phase of menstrual cycle, use of hormonal
contraceptives, menopause and use of estrogens greatly
impact on inﬂammation levels,
6–8 which could confound a
clear association between depression and inﬂammation.
However, in our study, associations between depression
and inﬂammation appeared absent in both pre- and post-
menopausal women and adjusting for several hormonal
factors did not change our ﬁndings. Another explanation
might be that in women, psychosocial factors have a larger
role in depression and therefore override the effects of
biological factors. For instance, insufﬁcient social support
andstressfullifeeventshavebeenfoundtoposeagreaterrisk
for depression among women compared with men.
26,27
Results of increased inﬂammation were particularly present
in men with late-onset depression. In contrast, characteristics
that are more often associated with an early age of onset,
such as higher severity and longer duration, were not
consistently associated with increased inﬂammation. Inter-
esting to note is that women in our study also had an earlier
age of depression onset compared with men. A distinct
etiology in late-onset versus early-onset depression was also
found by Kendler et al.
28 This study showed that depression
with an early age of onset was associated with a family history
ofdepression,whereaslate-onsetdepressionwasassociated
with a family history of vascular disease. Also, subclinical
vascular dysregulations, such as atherosclerosis, have been
found to relate to late-onset depression.
11,12 These ﬁndings
are in line with the vascular depression hypothesis, which
suggests that vascular damage in the brain predisposes to
late-onset depression.
29 As immune dysregulation is critically
involved in vascular disease,
13 this vascular damage could be
the result of increased inﬂammation.
Instead of inﬂammatory or vascular, the true etiology of
depressioninthissubgroupofmenwithlate-onsetdepression
might have a metabolic nature. Several studies have
conﬁrmed an association between CRP, IL-6 and TNF-a with
the metabolic syndrome and visceral fat depots release
cytokines.
30 The metabolic syndrome and in particular
visceral fat have been bidirectionally associated with depres-
sion in late life,
31,32 speciﬁcally in men. Men possess higher
amounts of visceral fat compared with women and are
therefore more likely to experience related inﬂammation and
depression. Involvement of metabolic processes is further
supported by our ﬁnding that the association between
depression and inﬂammation in particular decreased after
adjustment for BMI.
Several biological mechanisms could further explain the
relationship between depression and inﬂammation. Depres-
sion has been associated with dysregulation of important
stresssystems of the human body, that is, the hypothalamus–
pituitary–adrenal-axis
33andtheautonomicnervoussystem.
34
Although the hypothalamus–pituitary–adrenal-axis in normal
situations should temper inﬂammatory reactions, prolonged
hyperactivity of the hypothalamus–pituitary–adrenal-axis
could result in blunted anti-inﬂammatory responses to
glucocorticoids resulting in increased inﬂammation.
35,36 In
addition, both decreased parasympathetic
37 as well as
increased sympathetic nervous system activity
38 have been
associated with increased inﬂammation. Furthermore, pro-
inﬂammatory cytokines might inhibit hippocampal neurogen-
esis,
39 which could lead to a reduced hippocampal volume,
40
whichisalsoseenindepression.
41Also,severalinﬂammatory
markers have been shown to promote indoleamine-2,3-
dioxygenase activation,
42 which catalyzes tryptophan, the
precursor of serotonin, to kynurenine, thereby indirectly
reducing the availability of serotonin.
43 Lastly, speciﬁc genes
might underlie both increased inﬂammation and depression,
as several inﬂammation-related genes have been associated
with susceptibility to major depression.
44
Our study also shows that inﬂammation levels differ across
persons using different types of antidepressant medication.
The highest inﬂammation levels were found in men using
SNRI, TCAor TeCA,while IL-6 levelsinmen usingSSRI were
lower compared with medication-free depressed men. Inter-
esting to note is that the ﬁrst three classes of medication have
a combined serotonergic/noradrenergic effect, whereas SSRI
act purely serotonergic. Earlier studies found decreases in
inﬂammatory marker levels after antidepressant treatment,
mainly SSRI (see ref. 14 for an overview), whereas two recent
large studies found that use of antidepressants, mainly TCA,
was associated with elevated inﬂammation levels.
15 Possibly,
noradrenergic effects are driving increased inﬂammation
mechanisms. Noradrenaline is a part of the human stress
response and has been suggested to potentiate cytokine
production.
45 Use of SNRI, TCA and TeCA has also been
observed to disturb functioning of autonomic nervous sys-
tem,
46 blood pressure
47 and the metabolic syndrome.
48
Although it is possible that persons using SNRI, TCA or
TeCA are in other ways different from SSRI users and
medication-free depressed persons, we constructed our
groups in such a way that depression severity levels were
very comparable. In addition, we adjusted our analyses for a
large set of covariates and have therefore taken possible
differences in lifestyle or disease factors into account. On the
other hand, evidence suggests that increased inﬂammatory
activity before treatment predicts non-response.
49,50 Possi-
bly, persons with elevated inﬂammation did not respond to
SSRI and were therefore prescribed SNRI, TCA or TeCA.
Associations found in this study were not always consistent
across all inﬂammatory markers. Correlations between
inﬂammatory markers were only modest and were highest
between CRP and IL-6. Regulation of the immune system is
rather complex and involves many different inﬂammatory
mechanisms. Most consistent ﬁndings were found for CRP,
whichisaverygeneralmarkerofinﬂammation.IL-6andTNF-a,
on the other hand, only tap part of the immune system. This
seems to suggest that inﬂammation is indeed involved in
depression, but it is still unclear which part of the immune
system is most critically involved. Nonetheless, expected
associations with covariates (for example, age, smoking,
alcohol use, BMI, physical activity and somatic disease
(medication)) were found for all inﬂammatory markers.
What do the ﬁndings of our study implicate with regard to
treatment of depression? Considering the heterogeneity of
depressionandthefactthatcurrenttreatmentofdepressionis
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1,2 this
indicates that new treatments are needed for speciﬁc
subgroups. Our ﬁnding of increased inﬂammation in men with
late-onset depression, together with previous ﬁndings of high
inﬂammationindicatingnon-responsetoantidepressants,
49,50
might suggest that this speciﬁc subgroup could beneﬁt from
alternative treatments, with anti-inﬂammatory medication
being a likely candidate. Preliminary evidence from studies
amongpatientstreated withanti-inﬂammatory agentsforother
indications suggests that these agents may have beneﬁcial
effectsonmood.
51Onestudyfoundpositiveeffectsonmoodin
medically healthy, major depressed patients.
52 On the other
handwefound,likeothers,
14thatSSRImighthaveabeneﬁcial
effectoninﬂammation,suggestingthatSSRIcouldbeeffective
in depressed patients with immune dysregulation through this
anti-inﬂammatory effect. Furthermore, behavioral interven-
tions, such as exercise, have been shown to normalize
immune and metabolic dysregulation,
53 as well as to improve
depressive symptoms to some degree,
54 and might therefore
be an indicated treatment for a immune/metabolic depression
subgroup. At this moment, these considerations for treatment
implications are still very speculative. Follow-up (longitudinal)
researchshould conﬁrm andfurther delineatean inﬂammatory
(or metabolic) depression subtype, taking into account age,
sex, depression characteristics and course. Experimental
studies are needed to examine and compare the effects of
different types of currently available antidepressants, anti-
inﬂammatory medication and behavioral (exercise) interven-
tions on both immune/metabolic parameters and depression.
Our study has some important strengths such as a large
sample size, assessment of multiple inﬂammatory markers,
clinical diagnoses of depression, adequate adjustment for
potential confounders, the ability to examine the role of
depression characteristics and antidepressant medication.
However, some limitations need to be acknowledged. As our
data are cross-sectional, we cannot make any inferences
about the direction of the association. Longitudinal studies are
needed to investigate whether immune dysregulation is a
precursor or the result of depression (treatment), or whether
this relationship is bidirectional. The few available prospective
studies have shown contradicting results.
9,55,56 Further, like
most other studies, we assessed circulating levels of inﬂam-
matory markers, which show a high degree of intra-individual
variation, which could explain the rather modest overall
associations between depression and inﬂammation in our
study.
In conclusion, our study suggests that immune dysregula-
tion has a role in a subgroup of depressed persons, in
particular in men with a late-onset depression. Treatment
trials should further examine the differential effects of different
types of antidepressants on inﬂammation. Whether a speciﬁc
treatment strategy (SSRI, anti-inﬂammatory drugs, exercise)
is indicated for a subgroup of late-onset depressed patients
with immune dysregulation needs to be further investigated,
using longitudinal and experimental study designs.
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